Acute postoperative pain after thoracic surgery
Conditions
Interventions
RPB group:Ultrasound-guided single-shot thoracic paravertebral block with 20 mL of 0.375% ropivacaine .
LBB group:Ultrasound-guided single-shot thoracic paravertebral block with liposomal bupivacaine 133 mg (10 mL) diluted with 10 mL normal saline to a total volume of 20 mL.
Sponsors
The Second Affiliated Hospital of Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Voluntary participation with written informed consent; 2.age between 18 and 65 years; 3. either sex; 4. body mass index between 19.0 and 26.0 kg/m^2; 5.American Society of Anesthesiologists physical status II–III; 6. scheduled for elective thoracoscopic lobectomy at the Second Affiliated Hospital of Shandong First Medical University.
Exclusion criteria
Exclusion criteria: 1. Refusal of paravertebral nerve block: Patients who voluntarily refuse to receive paravertebral block treatment will not be included in the study; 2. History of allergies or immune-related diseases: Patients with known allergy to bupivacaine, or those suffering from immune-related diseases such as asthma, urticaria, or eczema, will be excluded; 3. Chest wall injury or infection: Patients with trauma, infection, or other local lesions in the chest wall area, which make effective nerve block impossible, do not meet the inclusion criteria; 4. Abnormal coagulation function: If preoperative test results show an APTT value exceeding 33.8 seconds or a PT value higher than 12.1 seconds, indicating abnormal coagulation function, the patient is not suitable for participation in the study; 5. History of chronic neuropathic pain: Patients with a history of chronic neuropathic pain may affect the effectiveness of nerve block and the accuracy of study results, and thus will not be included; 6. Participation in other clinical trials: Patients currently participating in other clinical studies may interfere with the results of this study and therefore do not meet the inclusion requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resting VAS pain scores at 1, 12, 24, 48, and 72 hours after surgery;Coughing VAS pain scores at 1, 12, 24, 48, and 72 hours after surgery;Cumulative opioid consumption within 72 hours after surgery;Incidence of opioid-related adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of recovery assessed by QoR-15;Sleep quality;Anxiety and depression status; | — |
Countries
China
Contacts
Public ContactWensheng Zhang
The Second Affiliated Hospital of Shandong First Medical University
Outcome results
None listed